Martijn van Essen

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 47:1599-606. 2006
  2. ncbi Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Nucl Med 51:383-90. 2010
  3. ncbi Peptide-receptor radionuclide therapy for endocrine tumors
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
    Nat Rev Endocrinol 5:382-93. 2009
  4. ncbi Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, s Gravendijkwal 230, Rotterdam, CE, The Netherlands
    Acta Oncol 46:723-34. 2007
  5. ncbi Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 34:1219-27. 2007
  6. ncbi Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 35:743-8. 2008
  7. ncbi Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Clin Oncol 26:2124-30. 2008
  8. ncbi Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Endocr Relat Cancer 17:R53-73. 2010
  9. ncbi Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
    Bart de Keizer
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 35:749-55. 2008
  10. ncbi Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate
    Saima Khan
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 52:1361-8. 2011

Detail Information

Publications12

  1. ncbi Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 47:1599-606. 2006
    ..Here we present the effects of this therapy in a small number of patients with metastasized or inoperable paragangliomas, meningiomas, small cell lung carcinomas (SCLCs), and melanomas...
  2. ncbi Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Nucl Med 51:383-90. 2010
    ..We present the effects of additional therapy with (177)Lu-octreotate in patients in whom progressive disease developed after an initial benefit from regular therapy...
  3. ncbi Peptide-receptor radionuclide therapy for endocrine tumors
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
    Nat Rev Endocrinol 5:382-93. 2009
    ..If these results can be replicated in large, controlled trials, PRRT might become the preferred option in patients with metastatic or inoperable gastroenteropancreatic neuroendocrine tumors...
  4. ncbi Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, s Gravendijkwal 230, Rotterdam, CE, The Netherlands
    Acta Oncol 46:723-34. 2007
    ..Also the role in somatostatin receptor expressing non-GEP tumours, like metastasised paraganglioma/pheochromocytoma and non-radioiodine-avid differentiated thyroid carcinoma might become more important...
  5. ncbi Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 34:1219-27. 2007
    ..As patients with foregut carcinoids may respond differently, we here present the effects of this treatment in a subgroup of patients with foregut carcinoids of bronchial, gastric or thymic origin...
  6. ncbi Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 35:743-8. 2008
    ..Adding capecitabine to (177)Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now present the short-term toxicity profile of this novel combination...
  7. ncbi Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Clin Oncol 26:2124-30. 2008
    ..Here we report on the toxicity and efficacy of this treatment, performed in over 500 patients...
  8. ncbi Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Endocr Relat Cancer 17:R53-73. 2010
    ..If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable GEPNETs...
  9. ncbi Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
    Bart de Keizer
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 35:749-55. 2008
    ..The aim of this study was to investigate the incidence of hormonal crises after therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate)...
  10. ncbi Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate
    Saima Khan
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 52:1361-8. 2011
    ..In this study, we investigated the QOL and symptoms after [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate) therapy in patients with inoperable or metastasized gastroenteropancreatic or bronchial neuroendocrine tumors (NETs)...
  11. ncbi Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Semin Nucl Med 40:78-88. 2010
    ..If more widespread use of peptide receptor radionuclide therapy can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable gastroenteropancreatic neuroendocrine tumors...
  12. ncbi Neoadjuvant downsizing by internal radiation: a case for preoperative Peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors
    Samer Ezziddin
    From the Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany Department of Surgery, Malteser Hospital Duisburg, Duisburg, Germany Oncology Center Duisburg, Duisburg, Germany Department of Radiology, University Hospital Bonn, Bonn, Germany and Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, Netherlands
    Clin Nucl Med 37:102-4. 2012
    ..The patient has been in complete local remission for 22 months. This case demonstrates the potential of preoperative PRRT to improve resectability of initially inoperable pancreatic endocrine tumors...